Endogenous regeneration: Engineering growth factors for stroke.

Area of Science:

• Neuroscience
• Regenerative Medicine
• Biotechnology

Background:

• Recombinant tissue plasminogen activator (rtPA) is the sole FDA-approved therapy for ischemic stroke, with a narrow therapeutic window.
• Regenerative medicine offers potential for brain tissue restoration in stroke by targeting endogenous growth factors.
• Translational studies of regenerative therapies for stroke have faced significant challenges and failures.

Purpose of the Study:

• To review the effects of key trophic factors in experimental ischemic stroke models.
• To analyze the ""lost in translation"" challenges for growth factor therapies from bench to bedside.
• To highlight novel bioengineering approaches for improving growth factor delivery and efficacy.

Main Methods:

• Review of experimental ischemic stroke models evaluating growth factors: erythropoietin (EPO), brain-derived neurotrophic factor (BDNF), granulocyte-colony stimulating factor (G-CSF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), epidermal growth factor (EGF), and heparin-binding epidermal growth factor (HB-EGF).
• Analysis of translational barriers encountered in preclinical to clinical progression.
• Examination of bioengineering strategies including hydrogel-based scaffolds for controlled release and glycosaminoglycan-mediated enhancement of growth factor half-life and selectivity.

Main Results:

• Various trophic factors demonstrate therapeutic potential in preclinical ischemic stroke models.
• Significant challenges exist in translating these growth factor therapies into effective clinical treatments.
• Hydrogel scaffolds and glycosaminoglycan modifications represent promising bioengineering solutions to overcome translational hurdles.

Conclusions:

• Growth factors hold significant therapeutic promise for ischemic stroke, but translation remains a challenge.
• Bioengineering approaches, such as controlled delivery systems and modified growth factors, are crucial for clinical success.
• Further development of these advanced methodologies is essential to realize the full potential of regenerative medicine for stroke.